# Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

> **NCT05289687** · PHASE2 · RECRUITING · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 20 (estimated)

## Conditions studied

- T-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Daratumumab / Hyaluronidase Injection
- **DRUG:** Daratumumab / Hyaluronidase Injection
- **DRUG:** Daratumumab / Hyaluronidase Injection
- **DRUG:** Daratumumab / Hyaluronidase Injection

## Key facts

- **NCT ID:** NCT05289687
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-25
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289687, "Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05289687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*